Preparation and Characterization of a Dry Powder Inhaler Composed of PLGA Large Porous Particles Encapsulating Gentamicin Sulfate

Abstract

<b><i>Purpose:</i></b> Direct delivery of aminoglycosides to the lungs was under extensive evaluations during the last decades. Because of large particle size, low density and porous structure, large porous particles (LPPs) are versatile carriers for this purpose. In this study, poly (lactic-co-glycolic acid) (PLGA) LPPs encapsulating gentamicin sulfate were prepared and <i>in vitro</i> characteristics of their freeze-dried powder as a dry powder inhaler (DPI) were evaluated. <b><i>Methods:</i></b> To prepare PLGA LPPs, a double emulsification-solvent evaporation method was optimized and gentamicin sulfate was post-loaded in the LPPs. <i>in vitro</i> characteristics including morphological features, thermal behavior, aerodynamic profile and cumulative drug release were evaluated by the scanning electron microscope (SEM), differential scanning calorimetry (DSC), next-generation cascade impactor (NGI) and Franz diffusion cell respectively. <b><i>Results:</i></b> The obtained results revealed that the preparation method was capable to produce spherical large homogenous highly porous particles. 94% of gentamicin sulfate released from LPPs up to 30 minutes. Mass median aerodynamic diameter (MMAD) and fine particle fraction (FPF) were 4.9 µm and 39% respectively. <b><i>Conclusion:</i></b> In this study, dry powder formulation composed of PLGA LPPs encapsulating gentamicin sulfate showed a promising <i>in vitro</i> behavior as a pulmonary delivery carrier. Improvements on the aerodynamic behavior and <i>in vivo</i> evaluations recommended for further developments.